China is rapidly making headway in phase 1 clinical trials, although the U.S. remains the world leader in phase 1 through 3 trials overall.
The U.S. had 614 phase 1 trial starts, followed by 194 in China and 147 in the UK, according to 2017 data reviewed by the Association of the British Pharmaceutical Industry (ABPI).
China, however, is still struggling in later phase startups. China scored ninth place for phase 2 startups with only 122 new trials, and 11th place in phase 3 trials with 146.
The report attributes the lack of late-phase Chinese trials to a lack of trained trial managers and an inefficient regulatory environment.